Topics

Companies Related to "Intrinsic connectomes predictive biomarker remission major depressive disorder" [Most Relevant Company Matches] RSS

02:56 EST 8th December 2019 | BioPortfolio

Here are the most relevant search results for "Intrinsic connectomes predictive biomarker remission major depressive disorder" found in our extensive corporate database of over 50,000 company records.

Showing "Intrinsic connectomes predictive biomarker remission major depressive disorder" Companies 1–25 of 1,900+

Extremely Relevant

CiTrials

At Clinical Innovations, our mission is to conduct Phase I-IV clinical trials in order to further the development of medications benefiting patients, communities, and physicians around the globe. Located in Southern California, CiTrials has the experience and expertise in performing Psychiatric and Internal medicine trials. From pediatric, first in human, single and multiple ascending dose, and...


Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. ...

Relevant

Targacept, Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Tar...


Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targace...

Greenbrook TMS Inc.

Operating through 47 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with...

Alfasigma USA

Alfasigma USA, Inc. is the American affiliate of Alfasigma, a leading Italian pharmaceutical company. Alfasigma is present in more than 90 countries, with a workforce of around 3,000 people and 5 manufacturing plants. Alfasigma USA, Inc. distributes a portfolio of prescription nutritional products to help individuals who are suffering from GI disorders (VSL#3®), major depressive disorder (DEPL...

Intrinsic Therapeutics, Inc.

Intrinsic Therapeutics is dedicated to treating soft-tissue injuries of the spine. Intrinsic's Barricaid anular reconstructive products are used during discectomy to definitively close defects in the posterior anulus. By restoring anular competence, the Barricaid family of products may reduce the risk of recurrent herniation while maintaining disc height and biomechanics.

HopeLab

HopeLab is a non-profit organization founded in 2001 by Board Chair Pam Omidyar. HopeLab combines rigorous research with innovative solutions to improve the health and quality of life of young people living with chronic illness. HopeLab applies a research-based, customer-focused development model to create products that address chronic illnesses in young people, including cancer, obesity, sic...

Targacept Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Tar...

Targos Molecular Pathology GmbH

"Targos focuses on the application, discovery and development of predictive biomarkers in oncology. Targeted therapies in oncology usually require biomarker guidance in development and clinical application for ethical, economic and regulatory reasons. Targos combines molecular pathology expertise with highly standardized analytics and applies strict project and quality management to provide the in...

Zoloft

Zoloft is well tolerated and effective for the treatment of depression and certain types of anxiety disorders. Zoloft is FDA approved to treat depression, social anxiety disorder, posttraumatic stress disorder (PTSD), panic disorder, obsessive-compulsive disorder (OCD), and premenstrual dysphoric disorder (PMDD) in adults over age 18. It is also approved for OCD in children and adolescents age 6-1...

BioMarker Strategies, LLC

BioMarker Strategies has developed SnapPath®, the only cancer diagnostics system that automates and standardizes functional ex vivo profiling of live solid tumor cells from fresh biopsies or other fresh, unfixed samples such as xenografts or tumorgrafts. SnapPath® can help guide cancer drug development and treatment selection. The Company’s Path...

BioMarker Strategies

BioMarker Strategies (www.biomarkerstrategies.com) is a cancer diagnostics company that is developing a novel biomarker testing system to improve the treatment of cancer. SnapPath™ incorporates an automated and proprietary live-tumor-cell processing device with first-in-class, ex vivo biomarker tests to predict patient response to targeted cancer ther...

ABL, Inc. and Aushon BioSystems

Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the Cira™ immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laborator...

BiomarkerBase

BiomarkerBase™ (http://www.biomarkerbase.com) includes every molecular biomarker on a drug label, every biomarker in a PMA-approved diagnostic, prognostic, or companion diagnostic (theranostic) test, and every biomarker in an active phase 3 or 4 clinical drug trial. All records in BiomarkerBase™ are linked directly to primary authorities such as ...

EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in ...

BioMarker Strategies LLC

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Maryland. Our mission is to help make personalized medicine more of a reality for patients with solid tumor cancers, by providing powerful new molecular tools and research services t...

Intrinsic Bioprobes, Inc.

Kaggle

Kaggle is the global leader in running predictive modeling competitions. The company has run approximately 100 competitions with major enterprise, government, and academic customers, including Allstate Insurance, Boehringer Ingelheim, Dunnhumby, Ford, Heritage Health, Microsoft, NASA, Stanford, and Wikipedia. Over 39,000 data scientists worldwide have cont...

Bring Change 2 Mind

In 2009 Ms. Close participated in the launch of Bring Change 2 Mind (www.bringchange2mind.org) a not-for-profit organization dedicated to confronting the stigma and discrimination associated with mental illness. Bring Change 2 Mind was created by Ms. Close together with Fountain House, IMHRO (International Mental Health Research Organization) and The Balanced Min...

Intrinsic LifeSciences

Intrinsic LifeSciences, The BioIron Company™, is a privately held California-based company focused on developing innovative tests that help improve the diagnosis and treatment of patients with life-threatening diseases. The company founders, Mark Westerman, Ph.D. and Professors Tomas Ganz, Ph.D. M.D., and Elizabeta Nemeth, Ph.D., (UCLA David Geffen Sc...

Quadrant Biosciences, Inc.

Quadrant Biosciences, Inc. is developing clinical assessment and molecular diagnostic tools to help physicians assess brain health and support more rapid accurate diagnoses of brain-based disorders. The company’s tests are expected to improve the diagnosis, monitoring and treatment of serious health conditions including autism spectrum disorder, concu...

HealthLinx Limited

HealthLinx is an emerging theranostics company and is formerly Cryptome Pharmaceuticals. Cryptome's acquisition of HealthLinx Pty. Ltd. has secured world-wide exclusive licenses for biomarkers that have application within the predictive diagnostic market-space, in particular for the diagnosis of cances and adds to its therapeutics focus. The company completed the merger on 14th February 2006 and o...

Quant HC

Quant HC is a predictive analytics medtech company based in Chicago, Illinois. It has partnered with Phillips Healthcare, Agile MD, Apervita, and others to offer its predictive algorithms to hospitals throughout the world. More information about Quant HC can be found at www.quanthc.com.

Pharmacology Research Institute

PRI is an internationally recognized research organization with expertise in pharmacological and multidisciplinary research. Our staff is experienced in the fields of psychiatry, cardiology, rheumatology, family practice, neurology, ophthalmology, gerontology, pharmacoeconomics and quality of life measures.Diagnostic categories treated have included adult attention deficit hyperactivity disorders ...


More From BioPortfolio on "Intrinsic connectomes predictive biomarker remission major depressive disorder"

Quick Search

Corporate Database Quicklinks